within Pharmacolibrary.Drugs.ATC.N;

model N06DA52
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.0001,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 600,            
    Vdp             = 0.003,
    k12             = 2,
    k21             = 2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06DA52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Donepezil and memantine is a fixed-dose combination used for the symptomatic treatment of moderate to severe Alzheimer's disease. Donepezil is an acetylcholinesterase inhibitor that improves cholinergic function, and memantine is an NMDA receptor antagonist that modulates glutamatergic neurotransmission. The drug combination is approved and used today for Alzheimer's disease therapy.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for the fixed combination in healthy adults; no direct published population pharmacokinetic data for the fixed-dose combination, values based on published data for individual drugs.</p><h4>References</h4><ol><li><p>Periclou, AP, et al., &amp; Abramowitz, WT (2004). Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. <i>The Annals of pharmacotherapy</i> 38(9) 1389–1394. DOI:<a href=\"https://doi.org/10.1345/aph.1D638\">10.1345/aph.1D638</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15266045/\">https://pubmed.ncbi.nlm.nih.gov/15266045</a></p></li><li><p>Bhateria, M, et al., &amp; Bhatta, RS (2015). Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1001 131–139. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2015.07.042\">10.1016/j.jchromb.2015.07.042</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26280281/\">https://pubmed.ncbi.nlm.nih.gov/26280281</a></p></li><li><p> (2013). Drugs for cognitive loss and dementia. <i>Treatment guidelines from the Medical Letter</i> 11(134) 95–p100.. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24081314/\">https://pubmed.ncbi.nlm.nih.gov/24081314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06DA52;
